Literature DB >> 23751076

Genome variation and personalized cancer medicine.

T J Hudson1.   

Abstract

Genomic variation, through effects on gene structure and expression, plays an important role in understanding disease predisposition, biology and clinical response to therapy. Transforming this knowledge into clinically relevant information that tailors interventions to an individual's specific genetic, physical, social and environmental profile is challenging. To illustrate how research initiatives at preclinical phases of development are attempting to address clinically important issues in oncology, six clinical problems related to cancers of the colon, prostate, breast, pancreas and brain (medulloblastoma) as well as metastatic disease of different origins are described. A unifying theme across applications is that healthy individuals previously indistinguishable in regards to cancer risk and patients with cancer previously categorized as similar with regard to prognosis or drug response are being stratified into more refined subgroups with different clinical profiles. Effective matching of a broad range of tests with more tailored strategies for prevention and/or treatment will require well-designed clinical studies to evaluate benefits and costs.
© 2013 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Keywords:  biomarkers; cancer; genomic medicine; personalized medicine

Mesh:

Year:  2013        PMID: 23751076     DOI: 10.1111/joim.12097

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  10 in total

1.  Common polymorphism in the MMP-13 gene may contribute to the risk of human cancers: a meta-analysis.

Authors:  Ping Gao; Jun-Lan Yang; Hong Zhao; Jun-Hao You; Yi Hu
Journal:  Tumour Biol       Date:  2014-07-15

2.  Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias.

Authors:  Abhishek A Mangaonkar; Alejandro Ferrer; Filippo Pinto E Vairo; Margot A Cousin; Ryan J Kuisle; Naseema Gangat; William J Hogan; Mark R Litzow; Tammy M McAllister; Eric W Klee; Konstantinos N Lazaridis; A Keith Stewart; Mrinal M Patnaik
Journal:  Mayo Clin Proc       Date:  2019-06-27       Impact factor: 7.616

3.  Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer.

Authors:  Endre Sebestyén; Michał Zawisza; Eduardo Eyras
Journal:  Nucleic Acids Res       Date:  2015-01-10       Impact factor: 16.971

Review 4.  Medulloblastoma development: tumor biology informs treatment decisions.

Authors:  Vidya Gopalakrishnan; Rong-Hua Tao; Tara Dobson; William Brugmann; Soumen Khatua
Journal:  CNS Oncol       Date:  2015

5.  NAT1 polymorphisms and cancer risk: a systematic review and meta-analysis.

Authors:  Kunyi Zhang; Lijuan Gao; Yuqi Wu; Jianyi Chen; Chengguang Lin; Shaohua Liang; Jianxin Su; Jinming Ye; Xuyu He
Journal:  Int J Clin Exp Med       Date:  2015-06-15

6.  Detection of lower levels of SNAP25 using multiple microarray systems and its functional significance in medulloblastoma.

Authors:  Chi-Jung Huang; Chia-Long Lee; Chih-Yi Liu; Shih-Hung Huang; Jia-Woei Hou; Yi-Hou Chen; Chih-Cheng Chien; Chih-Ming Ho; Wen-Cheng Lo; Kun-Long Hung
Journal:  Int J Mol Med       Date:  2017-03-20       Impact factor: 4.101

Review 7.  Single nucleotide alterations in MicroRNAs and human cancer-A not fully explored field.

Authors:  Dan Zhao
Journal:  Noncoding RNA Res       Date:  2020-02-19

8.  Associations between the Genetic Polymorphisms of Osteopontin Promoter and Susceptibility to Cancer in Chinese Population: A Meta-Analysis.

Authors:  Yulan Liu; Hongbo Lei; Jixiang Zhang; Jun Wang; Kui Li; Weiguo Dong
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

9.  A 26-hour system of highly sensitive whole genome sequencing for emergency management of genetic diseases.

Authors:  Neil A Miller; Emily G Farrow; Margaret Gibson; Laurel K Willig; Greyson Twist; Byunggil Yoo; Tyler Marrs; Shane Corder; Lisa Krivohlavek; Adam Walter; Josh E Petrikin; Carol J Saunders; Isabelle Thiffault; Sarah E Soden; Laurie D Smith; Darrell L Dinwiddie; Suzanne Herd; Julie A Cakici; Severine Catreux; Mike Ruehle; Stephen F Kingsmore
Journal:  Genome Med       Date:  2015-09-30       Impact factor: 11.117

10.  Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.

Authors:  Michail Shipitsin; Clayton Small; Eldar Giladi; Summar Siddiqui; Sibgat Choudhury; Sadiq Hussain; Yi E Huang; Hua Chang; David L Rimm; David M Berman; Thomas P Nifong; Peter Blume-Jensen
Journal:  Proteome Sci       Date:  2014-07-12       Impact factor: 2.480

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.